NasdaqGS:ADXS

Stock Analysis Report

Executive Summary

Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Risks

  • Advaxis has significant price volatility in the past 3 months.
  • Advaxis is covered by less than 3 analysts.

Share Price & News

How has Advaxis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.2%

NasdaqGS:ADXS

0.4%

US Biotechs

1.2%

US Market


1 Year Return

-97.5%

NasdaqGS:ADXS

-10.8%

US Biotechs

1.7%

US Market

ADXS underperformed the Biotechs industry which returned -10.8% over the past year.

ADXS underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

ADXSIndustryMarket
7 Day-8.2%0.4%1.2%
30 Day-24.0%0.3%4.9%
90 Day-86.0%1.6%3.7%
1 Year-97.5%-97.5%-10.1%-10.8%3.9%1.7%
3 Year-99.8%-99.8%7.3%3.6%47.2%37.7%
5 Year-99.4%-99.4%2.9%-2.0%60.0%42.4%

Price Volatility Vs. Market

How volatile is Advaxis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Advaxis undervalued based on future cash flows and its price relative to the stock market?

0.12x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Advaxis to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Advaxis to establish if it is available at substantial discount.


Price Based on Earnings

Advaxis is loss making, we can't compare its value to the US Biotechs industry average.

Advaxis is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Advaxis, we can't assess if its growth is good value.


Price Based on Value of Assets

Advaxis is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Advaxis expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-25.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Advaxis's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Advaxis is not considered high growth as it is expected to be loss making for the next 1-3 years.

Advaxis's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Unable to compare Advaxis's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Advaxis's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Advaxis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Advaxis performed over the past 5 years?

-11.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Advaxis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Advaxis's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Advaxis's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Advaxis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Advaxis has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Advaxis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Advaxis's financial position?


Financial Position Analysis

Advaxis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Advaxis's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Advaxis has no debt.

Advaxis has no debt compared to 5 years ago when it was 0.3%.


Balance Sheet

Low level of unsold assets.

Advaxis has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Advaxis has less than a year of cash runway based on current free cash flow.

Advaxis has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.3% each year.


Next Steps

Dividend

What is Advaxis's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Advaxis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Advaxis's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Advaxis has not reported any payouts.

Unable to verify if Advaxis's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Advaxis has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Advaxis's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

Ken Berlin (55yo)

1.4yrs

Tenure

US$1,797,456

Compensation

Mr. Kenneth A. Berlin, also known as Ken, J.D., serves as President, Chief Executive Officer and Director of Advaxis, Inc. since April 23, 2018. He served as the Chief Executive Officer and President of Ro ...


CEO Compensation Analysis

Ken's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Ken to compare compensation growth.


Management Age and Tenure

1.4yrs

Average Tenure

58yo

Average Age

The average tenure for the Advaxis management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.6yrs

Average Tenure

59yo

Average Age

The tenure for the Advaxis board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$11,39111 Apr 19
Roni Appel
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,000
Max PriceUS$3.80
SellUS$2,29907 Nov 18
Robert Petit
EntityIndividual
Role
Chairman of Advisory Board
Chairman of Scientific Advisory Board
Shares264.2
Max PriceUS$8.70
SellUS$4,75505 Nov 18
Robert Petit
EntityIndividual
Role
Chairman of Advisory Board
Chairman of Scientific Advisory Board
Shares566.07
Max PriceUS$8.40

Ownership Breakdown


Management Team

  • Tony Lombardo (70yo)

    Executive Officer

    • Tenure: 1.4yrs
    • Compensation: US$967.80k
  • Molly Henderson (48yo)

    Executive VP

    • Tenure: 1.3yrs
    • Compensation: US$521.87k
  • Andres Gutierrez (58yo)

    Executive VP & Chief Medical Officer

    • Tenure: 1.4yrs
  • Ken Berlin (55yo)

    President

    • Tenure: 1.4yrs
    • Compensation: US$1.80m
  • Robert Petit (59yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0.3yrs
    • Compensation: US$730.69k
  • Ranya Dajani

    Vice President of Business Development

    • Tenure: 2.7yrs

Board Members

  • Richard Berman (76yo)

    Independent Director

    • Tenure: 14yrs
    • Compensation: US$141.60k
  • Roni Appel (52yo)

    Independent Director

    • Tenure: 14.8yrs
    • Compensation: US$122.50k
  • Jim Patton (61yo)

    Vice Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$189.25k
  • David Sidransky (59yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$203.55k
  • Jedd Wolchok

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Toni Ribas

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Ken Berlin (55yo)

    President

    • Tenure: 1.4yrs
    • Compensation: US$1.80m
  • Robert Petit (59yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0.3yrs
    • Compensation: US$730.69k
  • Samir Khleif (55yo)

    Independent Director

    • Tenure: 4.9yrs
    • Compensation: US$130.00k
  • Nancy Freitag

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Advaxis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advaxis, Inc.
  • Ticker: ADXS
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.598m
  • Shares outstanding: 24.71m
  • Website: https://www.advaxis.com

Number of Employees


Location

  • Advaxis, Inc.
  • 305 College Road East
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADXSNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJul 2005
FAD2DB (Deutsche Boerse AG)YesCommon SharesDEEURJul 2005

Biography

Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:21
End of Day Share Price2019/09/13 00:00
Earnings2019/07/31
Annual Earnings2018/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.